Interplay of parathyroid hormone and aldosterone antagonist in prevention of heart failure hospitalizations in chronic kidney disease

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 15, Issue 3, 2014, Pages 278-285

  Hassan, Mona ^a   Qureshi, Waqas ^b   Sroujieh, Laila S ^a   Albashaireh, Derar ^a   Boumalham, Sara ^a   Liroff, Meghan ^a   Amjad, Waseem ^c   Khalid, Fatima ^b   Hadid, Hiba ^a   Alirhayim, Zaid ^d  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c ALLAMA IQBAL MEDICAL COLLEGE   (Pakistan)

^d UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Aldosterone antagonist; chronic kidney disease; heart failure hospitalization

Indexed keywords

ANTIHYPERTENSIVE AGENT; PARATHYROID HORMONE; RETINOL; SPIRONOLACTONE; ALDOSTERONE; MINERALOCORTICOID ANTAGONIST;

AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HAZARD RATIO; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PRESCRIPTION; PROPORTIONAL HAZARDS MODEL; BLOOD; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; COMPLICATION; KAPLAN MEIER METHOD; METABOLISM;

AGED; ALDOSTERONE; CASE-CONTROL STUDIES; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PARATHYROID HORMONE; RENAL INSUFFICIENCY, CHRONIC; SPIRONOLACTONE;

EID: 84909950400     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320314539180     Document Type: Article

References (37)

1. Biermann J, Neumann T, Angermann CE, et al. Economic burden of patients with various etiologies of chronic systolic heart failure analyzed by resource use and costs. Int J Cardiol. 2012 ; 156: 323-325
2. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: A policy statement from the American Heart Association. Circulation. 2011 ; 123: 933-944
3. Jaarsma T, Van Der Wal MH, Hogenhuis J, et al. Design and methodology of the coach study: A multicenter randomised coordinating study evaluating outcomes of advising and counselling in heart failure. Eur J Heart Fail. 2004 ; 6: 227-233
4. Khalid F, Qureshi W, Qureshi S, et al. Impact of restarting warfarin therapy in renal disease anticoagulated patients with gastrointestinal hemorrhage. Ren Fail. 2013 ; 35: 1228-1235
5. Altay H, Colkesen Y.. Parathyroid hormone and heart failure: Novel biomarker strategy. Endocr Metab Immune Disord Drug Targets. 2013 ; 13: 100-104
6. Sugimoto T, Dohi K, Onishi K, et al. Interrelationship between haemodynamic state and serum intact parathyroid hormone levels in patients with chronic heart failure. Heart. 2013 ; 99: 111-115
7. Altay H, Zorlu A, Binici S, et al. Relation of serum parathyroid hormone level to severity of heart failure. Am J Cardiol. 2012 ; 109: 252-256
8. Loncar G, Bozic B, Dimkovic S, et al. Association of increased parathyroid hormone with neuroendocrine activation and endothelial dysfunction in elderly men with heart failure. J Endocrinol Invest. 2011 ; 34: e78 - e85
9. Sugimoto T, Tanigawa T, Onishi K, et al. Serum intact parathyroid hormone levels predict hospitalisation for heart failure. Heart. 2009 ; 95: 395-398
10. Brown JM, Williams JS, Luther JM, et al. Human interventions to characterize novel relationships between the renin-angiotensin-aldosterone system and parathyroid hormone. Hypertension. 2014 ; 63: 273-280
11. Hamdy NA, Kanis JA, Beneton MN, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. Brit Med J. 1995 ; 310: 358-363
12. Arenas MD, Alvarez-Ude F, Torregrosa V, et al. Consequences of the implementation of K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease in a population of patients on chronic hemodialysis. J Nephrol. 2007 ; 20: 453-461
13. Bailie GR, Massry SG.. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease: An overview. Pharmacotherapy. 2005 ; 25: 1687-1707
14. Am J Kidney Dis. 2003 ; 42: S1 - S201
15. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Int Med. 2009 ; 150: 604-612
16. Lima MV, Ochiai ME, Cardoso JN, et al. Hyperkalemia during spironolactone use in patients with decompensated heart failure. Arq Bras Cardiol. 2008 ; 91: 177 194-182 179
17. Edwards NC, Steeds RP, Chue CD, et al. The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. Br J Clin Pharmacol. 2012 ; 73: 447-454
18. Heshka J, Ruzicka M, Hiremath S, et al. Spironolactone for difficult to control hypertension in chronic kidney disease: An analysis of safety and efficacy. J Am Soc Hypertens. 2010 ; 4: 295-301
19. Schierbeck LL, Jensen TS, Bang U, et al. Parathyroid hormone and vitamin D-markers for cardiovascular and all cause mortality in heart failure. Eur J Heart Fail. 2011 ; 13: 626-632
20. Chhokar VS, Sun Y, Bhattacharya SK, et al. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation. 2005 ; 111: 871-878
21. Sim JJ, Shi J, Calara F, et al. Association of plasma renin activity and aldosterone-renin ratio with prevalence of chronic kidney disease: The Kaiser Permanente Southern California cohort. J Hypertens. 2011 ; 29: 2226-2235
22. Ponda MP, Hostetter TH.. Aldosterone antagonism in chronic kidney disease. Clin J Am Soc Nephrol. 2006 ; 1: 668-677
23. Hostetter TH, Ibrahim HN.. Aldosterone in chronic kidney and cardiac disease. J Am Soc Nephrol. 2003 ; 14: 2395-2401
24. Pilz S, Kienreich K, Drechsler C, et al. Hyperparathyroidism in patients with primary aldosteronism: Cross-sectional and interventional data from the GECOH study. J Clin Endocrinol Metab. 2012 ; 97: E75 - E79
25. Tomaschitz A, Pilz S. Interplay between sodium and calcium regulatory hormones: A clinically relevant research field. Hypertension. 2014 ; 63: 212-214
26. Ohtani T, Ohta M, Yamamoto K, et al. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker. Am J Physiol Regul Integr Comp Physiol. 2007 ; 292: R946 - R954
27. Gruson D, Lepoutre T, Ahn SA, et al. Comparison between intact and bioactive parathyroid hormone assays in patients with severe heart failure. Clin Biochem. 2013 ; 46: 391-394
28. Hagstrom E, Ingelsson E, Sundstrom J, et al. Plasma parathyroid hormone and risk of congestive heart failure in the community. Eur J Heart Fail. 2010 ; 12: 1186-1192
29. Diez-Perez A, Nogues X, Mellibovsky L, et al. Bone mass, vitamin D deficiency and hyperparathyroidism in congestive heart failure. Am J Med. 1998 ; 105: 358-359
30. Zittermann A, Schleithoff SS, Gotting C, et al. Poor outcome in end-stage heart failure patients with low circulating calcitriol levels. Eur J Heart Fail. 2008 ; 10: 321-327
31. Laguardia SP, Dockery BK, Bhattacharya SK, et al. Secondary hyperparathyroidism and hypovitaminosis D in African-Americans with decompensated heart failure. Am J Med Sci. 2006 ; 332: 112-118
32. Khouzam RN, Dishmon DA, Farah V, et al. Secondary hyperparathyroidism in patients with untreated and treated congestive heart failure. Am J Med Sci. 2006 ; 331: 30-34
33. Tomaschitz A, Ritz E, Pieske B, et al. Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. Metabolism. 2014 ; 63: 20-31
34. Smith DH, Thorp ML, Gurwitz JH, et al. Chronic kidney disease and outcomes in heart failure with preserved versus reduced ejection fraction: The Cardiovascular Research Network Preserve study. Circ Cardiovasc Qual Outcomes. 2013 ; 6: 333-342
35. McAlister FA, Ezekowitz J, Tarantini L, et al. Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: Impact of the new Chronic Kidney Disease-Epidemiology Collaboration group formula. Circ Heart Fail. 2012 ; 5: 309-314
36. Neil CJ, Singh S, Frenneaux M. Aldosterone inhibition in patients with heart failure with preserved ejection fraction. JAMA. 2013 ; 310: 205-207
37. Patel K, Fonarow GC, Kitzman DW, et al. Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2013 ; 1: 40-47